The consensus price target for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has increased from $19.14 to $23.50, indicating growing analyst optimism. Significant interest from major financial instituti

The stock consensus target price for Civeo Corporation (NYSE:CVEO) remains stable at $33, indicating a positive shift in analyst sentiment. Civeo's Australian segment is a key growth driver, with a r

UroGen Pharma Ltd. (NASDAQ:URGN) reported a quarterly loss of $0.54 per share, outperforming the Zacks Consensus Estimate. The company achieved $37.84 million in revenue for Q4 2025, surpassing expec

Executive insider transactions at Viavi Solutions Inc. (NASDAQ:VIAV) may signal internal sentiment towards the company's future performance. Despite negative earnings, Viavi's valuation metrics like

Stifel Nicolaus predicts a 24.69% increase in Apple's stock following the unveiling of new iPhone and iPad Air models. Apple introduces the iPhone 17e with advanced features and the iPad Air with a s

uniQure BV (NASDAQ:QURE) was downgraded by RBC Capital from "Outperform" to "Sector Perform" with a stock price of $9.94. The company reported a quarterly loss of $0.56 per share, outperforming the Z